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Abstract
Background: Concurrent chemoradiotherapy (CCRT) after breast surgery was investigated by few authors and
remains controversial, because of concerns of toxicity with taxanes/anthracyclines and radiation. This treatment is
not standard and is more commonly used for locally advanced breast cancer. The aim of our study was to evaluate
the efficacy and safety of the concomitant use of anthracycline with radiotherapy (RT).
Findings: Four hundred women having operable breast cancer, treated by adjuvant chemotherapy (CT) and RT in
concomitant way between January 2001 and December 2003, were included in this retrospective cohort study. The
study compares 2 adjuvant treatments using CCRT, the first with anthracycline (group A) and the second with CMF
(group B). The CT treatment was repeated every 21 days for 6 courses and the total delivered dose of RT was 50
Gy, divided as 2 Gy daily fractions. Locoregional recurrence free (LRFS), event free (EFS), and overall survivals (OS)
were estimated by the Kaplan-Meier method. The log-rank test was used to compare survival events. Multivariate
Cox-regression was used to evaluate the relationship between patient characteristics, treatment and survival.
In the 2 groups (A+B) (n = 400; 249 in group A and 151 in group B), the median follow-up period was 74.5
months. At 5 years, the isolated LRFS was significantly higher in group A compared to group B (98.7% vs 95.3%;
hazard ratio [HR] = 0.258; 95% CI, 0.067 to 0.997; log-rank P = .034). In addition, the use of anthracycline regimens
was associated with a higher rate of 5 years EFS (80.4% vs 75.1%; HR = 0.665; 95% CI, 0.455 to 1.016; log-rank
P = .057). The 5 years OS was 83.2% and 79.2% in the anthracycline and CMF groups, respectively (HR = 0.708; 95%
CI, 0.455 to 1.128; log-rank P = .143). Multivariate analysis confirmed the positive effect of anthracycline regimens
on LRFS (HR = 0.347; 95% CI, 0.114 to 1.053; log-rank P = .062), EFS (HR = 0.539; 95% CI, 0.344 to 0.846; P = 0.012),
and OS (HR = 0.63; 95% CI, 0.401 to 0.991; P = .046). LRFS, EFS and OS were significantly higher in the anthracy-
cline group where the patients (n = 288) received more than 1 cycle of concurrent CT (P = .038, P = .026 and
P = .038, respectively). LRFS and EFS were significantly higher in the anthracycline group within the BCT subgroup
(P = .049 and P = .04, respectively). There were more hematologic, and more grade 2/3/4 skin toxicity in the
anthracycline group.
Conclusions: After mastectomy or BCT, the adjuvant treatment based on anthracycline and concurrent RT reduced
breast cancer relapse rate, and significantly improved LRFS, EFS and OS in the patients receiving more than 1 cycle
of concurrent CT. There were more hematologic and non hematologic toxicities in the anthracycline group.
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In the case of radical mastectomy or breast conservative
therapy (BCT), adjuvant radiotherapy (RT), improves local
control [1-9]. Adjuvant chemotherapy (CT) is equally
mandatory for diminishing metastatic recurrences [10-12].
The optimal sequence of CT and RT remains contro-
versial. The delivery of RT can be planned before or
after CT, concurrently, or within 2 cycles of CT (’’sand-
wich’’ therapy). However, the current standard is CT fol-
lowed by whole-breast-irradiation (WBI). The delay of
CT increased the incidence of spared metastasis [13-16],
and the delay of RT induced more frequent local recur-
rences [17-19].
Concurrent treatment shortens the duration of ther-
apy, allows RT and CT to start temporally, and poten-
tially improves local control via the radiation sensitizing
effects of CT. Concurrent chemoradiotherapy (CCRT)
has successfully been achieved with cyclophosphamide,
methotrexate and fluorouracil (CMF) [20-22]. The con-
current use of taxanes and WBI seems feasible [23].
Anthracycline regimens improve survival in the adju-
vant setting [24]. Unfortunately, concomitant use of
epirubicin or doxorubicin produced 30% to 44% rate of
high grade radiation dermatitis (RD) [25,26], and con-
current mediastinal irradiation with doxorubicin induced
intense cardiac dysfunction [27]. This was discouraging
the use of anthracyclines and radiation concurrently.
However, in a previous study conducted in our institute
we showed that CCRT using anthracycline and WBI pro-
duced only 4.5% of ≥ grade 2 RD, and improved the
locoregional control over the treatment based on CMF
[28]. And recently, in another study, the authors con-
firmed the feasibility of partial breast irradiation (PBI)
with concurrent dose-dense doxorubicin and cyclopho-
sphamide in early breast cancer [29].
The present work, by including more patients, had the
objective to confirm our previous results and to support
the feasibility and efficiency of concomitant use of
anthracycline [28,30]. It was based on the study of a data
base of 400 patients treated by radical surgery (mastect-
omy or breast conservative therapy [BCT]) and adjuvant
CCRT. We compared the efficacy, and tolerability of two
concomitant protocols, the first with anthracycline based
regimens and the second with CMF regimen.
Methods
1. Patient selection
Eligibility
From January 2001 to December 2003, 400 women with
pathological confirmed breast cancer at stages pT1-T4/
pN0-3, without any evidence of metastatic disease, who
received complete excision of the primary tumor (mas-
tectomy or BCT) and treated with adjuvant CCRT, were
selected at the National Institute of Oncology in Rabat,
for investigation.
Two hundred forty four of the cases analyzed in the
present study have been the subject of one previous
published report [28].
Patient medical records (demographic data, disease
stages, histological findings, treatment and outcome)
were analyzed retrospectively. Radiological, pathological
and surgical reports were reviewed to determine the
stage of the disease [31]. The diagnostic instrumental
examinations used to stage the patients were chest
radiograph, abdominal ultrasound performed in all
patients, and bone scan (performed in only 15.2% of the
patients [n = 61]).
Exclusion criteria
Metastatic breast cancer or incomplete excision of the
primary tumour, and patients treated with sequential
chemo-radiotherapy.
2. Treatment planning (Figure 1)
The patients from which 84.8% (n = 361) had radical
surgery and 15.2% (n = 61) had BCT, were divided into
two groups on the basis of CT treatment. In group A
the treatment was based on anthracycline and in group
B the treatment was based on CMF. The median num-
ber of CT cycles delivered concurrently with RT was 2
(ranging from 1 to 5).
Group A (n = 249) received CCRT with anthracycline
based regimen and group B (n = 151) received CCRT
with CMF regimen.
Radiotherapy
For 96.5% of patients, RT was delivered to the whole
breast or to thoracic wall (99.2% in group A and 92.1%
in group B). The other 3.5% received only RT in the
lymph node region, this can be explained by the fact
that these patients had small tumors (pT1-pT2), and
received mastectomy with inadequate axillary dissection.
93.3% of the patients received an additional treatment
RT delivered to the regional lymph nodes.
All patients were treated with external beam RT using
tangential fields of Co- 60-gamma-Ray. The total deliv-
ered dose was 50 Gy, divided as 2 Gy daily fractions.
A complementary treatment was given by electrons or
by breast brachytherapy (10 to 20 Gy) for 28 patients.
Chemotherapy
The rational of choice of CT was not precised in the
patient files. The use of anthracycline regimen was justi-
fied by more aggressive tumors and by the lack of avail-
ability of other CT drugs.
Chemotherapy consisted of:
- In group A: a- intravenous AC60 (doxorubicin
60 mg/m
2 and cyclophosphamide 600 mg/m
2)o n
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Page 2 of 11day 1, repeated every 21 days for six courses for 173
patients, b- intravenous FEC75 (5-fluorouracile 500
mg/m
2, epirubicin 75 mg/m
2, and cyclophosphamide
500 mg/m
2) on day 1, repeated every 21 days for six
courses for 37 patients and c- intravenous FAC50
(5-fluorouracile 500 mg/m
2,d o x o r u b i c i n5 0m g / m
2,
and cyclophosphamide 500 mg/m
2) on day 1, repeated
every 21 days for six courses for 26 patients, and
d- Thirteen patient received sequential treatment
based on 2 different regimens, the first based on
anthracycline and the second based on CMF, repeated
every 21 days for six courses (table S1 [additional file
1]). The timing of CCRT was summarized in table S1
(additional file 1).
- In group B: intravenous CMF (cyclophosphamide
500 mg/m
2, methotrexate 60 mg/m
2, and 5-fluorour-
acil 500 mg/m
2) on day 1, repeated every 21 days for
six courses for 151 patients.
Hormone therapy
Adjuvant 5-year tamoxifen was initiated at the end of
the CCRT treatment in patients having positive hor-
mone receptor status.
3. Study endpoints
We retrospectively compared locoregional recurrence
free survival (LRFS), event free survival (EFS), overall
survival (OS), and toxicity between 2 therapeutic groups
A and B and between the subgroups within A and B.
The primary outcomes were LRFS and EFS, and the sec-
ondary outcomes were OS and safety.
4. Toxicity evaluation
The hematologic toxicity was measured through labora-
tory tests. Only the highest grades of toxicity were con-
sidered in the analysis.
Information about non-hematologic toxicities (der-
matitis toxicity, cardiac toxicity, and pulmonary toxi-
city) was not routinely collected. Only few high grades
toxicities (≥grade 2) were noted in our data base. This
constitutes a major limitation of our retrospective
study.
5. Statistical analysis
LRFS, EFS and OS were calculated from the date of
diagnosis (fine needle aspiration, biopsy) or surgery to
Figure 1 Study design. BCT = breast conservative therapy.
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Page 3 of 11the date of first documented locoregional relapse, and/or
to the date of death and last follow-up.
LRFS was of 2 types: in type 1, the events considered
were locoregional and occurred in the breast and/or
chest wall and/or regional lymph nodes, with or without
concurrent metastatic recurrence; in type 2 (isolated
LRFS), the events occurred concurrently with metastatic
recurrence were not considered.
The Kaplan-Meier method was used to estimate the
rates of LRFS, EFS, and OS [32]. The log-rank-test was
used to evaluate the differences between the groups.
The distribution homogeneity was analyzed with the
Pearson-chi
2-test for both groups. The p values were
based on two sided tests and conducted at a 5% signifi-
cance level
Univariate and multivariateu n i v a r i a t eC o xp r o p o r -
tional hazard regression models analysis was used to
evaluate the relationship between survival (LRFS, EFS,
and OS), treatment regimen (anthracycline vs CMF),
and patient characteristics (age, lymph node involve-
ment, tumour volume, tumour grade, hormonal receptor
status, number of cycle of concurrent CT) [33]. Candi-
date prognostic factors for LRFS, EFS, and OS, with a
0.5 level of significance in univariate analysis were
entered in a multivariate Cox model.
Statistical evaluation was carried out using SPSS 17.0
statistical software.
6. Subgroup Analyses
The first subgroup concerned the patients who received ≥
2 cycles of concurrent CT (n = 288), and the second sub-
group concerned the patients treated with BCT (n = 61).
7. Consent and statement of ethical approval
As the treatment was decided by the medical staff of the
centre depending on the availability of drugs in Mor-
occo, oral consent was obtained from the subjects and
was approved by the institutional review boards of the
National Institute of Oncology Cancer Centre in Rabat
This study was approved by the institutional review
boards of the National Institute of Oncology Cancer
Centre in Rabat.
This research is in compliance with the Helsinki
Declaration
Results
1. Patient characteristics
Median age was 44 years (range: 22 - 69 years) in group
A and 46 years (26 - 95 years) in group B.
The distribution of patient characteristics was partly
imbalanced. After the analysis of characteristics homo-
geneity within the two groups, we found more women
aged less than 40 years (P = .001), more lymph node
involvement (P = .019) in group A than in group B, and
less patients were menopaused in group A. In addition,
we found in group B that more patients received more
than 1 cycle of CT concurrently with RT (P < .001)
(table 1).
The analysis of characteristics homogeneity within the
subgroup of patients (n = 288) treated with ≥ 2c y c l e so f
concurrent CT showed that more patients in the anthracy-
cline subgroup were younger than 40 (P = .044) and there
was more lymph nodes involvement (P = .009) within
anthracycline subgroup (table S2 [additional file 2]).
Sixty one patients were treated with BCT, 40 of them
received anthracycline based CT and the remaining 21
received CMF. The characteristics homogeneity was also
analyzed between theses small subgroups (table S3
[additional file 3]).
The median delay of CT after surgery was 6.8 weeks
(range: 1 to 60 weeks), and the median delay of RT after
surgery was 14.8 weeks (range: 2 to 60 weeks). In the 2
groups A and B respectively, 93.6% and 98% of the
patients received the 6 courses of CT. All patients in the
two groups received 100% of the planned RT dose.
2. Treatment compliance
The hematologic toxicity was determined in 394 cases.
The percentage of patients which developed grade 2-3
anemia was 10.1% vs 6.1% in group A and B respectively
(chi
2-test, P = .172). Grade 3-4 neutropenia was present
in 14.6% of the cases in group A vs 7.6% of cases in
group B (chi
2-test, P = .036). Grade ≥ 2 thrombopenia
was found in 1.2% of the cases in group A vs 0.7% of
the cases in group B (chi
2-test, P = .6).
There was no cardiac toxicity that was clinically detect-
able in the two arms. The left ventricular fraction ejec-
tion (LVFE) was evaluated in only 9 patients (2 patients
in the anthracycline group and 7 in the CMF group), and
was normal (LVFE ranged between 63% and 87%).
In group A (n = 249), 12 patients (4.8%) had ≥ grade 2
RD toxicity, vs 2 patients (1.3%) in group B (n = 151)
(chi
2-test, P = .065).
Six patients in the anthracycline group showed
respiratory symptoms (dry cough in 5 patients and chest
pain in 1 patient) vs 0 patients in the CMF group (chi
2-
test, P = .055).
3. Outcomes
3.1 Outcomes in group A plus group B (n = 400)
LRFS (type 1) After 72.9 months (72.8 for group A, and
73.3 for group B) median follow-up (range: 4.5 - 99
months), loco-regional relapse was developed by 6
patients in the anthracycline group and by 8 patients in
the CMF group. The 5 years LRFS rate was equal to
97.1% in group A vs 94.6% in group B (hazard ratio
[HR] = 0.454; 95% CI, 0.157 to 1.308; log-rank P = .133)
(Figure 2A).
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Page 4 of 11Table 1 Demographic, clinical, histological, molecular and treatment characteristics of all patients (n = 400) and
analysis of groups homogeneity (Pearson Chi
2-test)
Characteristics Group A [n = 249] No (%) Group B [n = 151] No (%) P value
Age
<4 0 76 (30.5%) 25 (16.6%) 0.001
≥ 40 173 (69.5%) 122 (83.4%)
Menopausal status
No 178 (71.5%) 85 (56.3%) 0.008
Yes 60 (24.1%) 56 (37.1%)
Unknown 11 (4.4%) 10 (6.6%)
Side
Right 128 (51.4%) 72 (47.7%) 0.552
Left 120 (48.2%) 79 (52.2%)
Bilateral 1 (0.4%) 0
Surgery
Mastectomy 209 (83.9%) 130 (86.1%) 0.561
BCT 40 (16.1%) 21 (13.9%)
Histology
DIC 231 (92.8%) 136 (90.1%) 0.248
LIC 12 (4.8%) 13 (8.6%)
Other 10
Unknown 5 (2%) 2 (1.3%)
SBR
I 15 (6%) 12 (7.9%) 0.72
II 153 (61.4%) 97 (64.2%)
III 74 (29.7%) 38 (25.2%)
Unknown 7 (2.8%) 4 (2.6%)
Hormonal Receptor
ER+/PR+ 123 (49.4%) 84 (55.6%) 0.205
ER+/PR- 31 (12.4%) 25 (16.6%)
ER-/PR+ 25 (10%) 12 (7.9%)
ER-/PR- 65 (26.1%) 28 (18.5%)
Unknown 5 (2%) 2 (1.3%)
Tumour
pT1 28 (11.2%) 21 (13.9%) 0.867
pT2 142 (57%) 84 (55.6%)
pT3 63 (25.3%) 35 (23.2%)
pT4 12 (4.8%) 7 (4.6%)
Unknown 4 (1.6%) 4 (2.6%)
pN, axillary
pN0 44 (17.7%) 42 (27.8%) 0.009
pN1 69 (27.7%) 46 (30.5%)
pN2 77 (30.9%) 47 (31.1%)
pN3 50 (20.1%) 13 (8.6%)
Unknown 9 (3.6%) 3 (2%)
Number of cycle of CT delivered with RT
1 87 (34.9%) 25 (16.6%) < 0.001
≥ 2 162 (65.1%) 126 (83.4%)
Breast/thoracic wall irradiation
No 2 (0.8%) 12 (7.9%) < 0.001
Yes 247 (99.2%) 139 (92.1%)
Prophylactic supraclavicular fossa radiotherapy
No 17 (6.8%) 10 (6.6%) 0.556
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Page 5 of 11Isolated LRFS (type 2) When only isolated locoregional
events were considered for the evaluation of LRFS, loco-
regional relapse was developed by 3 patients in anthra-
cycline group and by 7 patients in the CMF group. The
5 years LRFS rate was significantly higher in group A
(98.7%) than group B (95.1%) (HR = 0.258; 95% CI,
0.067 to 0.997; log-rank P = .034) (Figure 2B).
Event free survival For EFS, the median follow-up period
was 71.2 (72.4 in group A and 64.5 in group B) months
(range: 4.5 - 99 months). EFS was evaluated in group A +
group B, 86 of whom had experienced an event (relapse
or death) at the last follow-up (in anthracycline group: 45
of 249; in CMF group: 41 of 151). The 5 years EFS rate
was 80.4% in group A vs 75.1% in group B, a difference
which tended to significance (HR = 0.665; 95% CI, 0.455
to 1.016; log-rank P = .057) (Figure 2C).
Overall survival For OS, the median follow-up period
was 74.5 (74.5 for group A and 74.6 for group B) months
(range, 4.5 - 106.6 months). Seventy-two patients died, 38
in group A and 34 in group B. The 5 years OS rate was
Figure 2 Comparison of the anthracycline group (group A, n = 249) with the CMF group (group B, n = 151) performed in the whole
group of patients (n = 400): Kaplan-Meier estimates of LRFS when all locoregional relapses were considered (Panel A), LRFS when only the
isolated locoregional relapses were considered (Panel B), EFS (Panel C), and OS (Panel D). LRFS = locoregional recurrence free survival; EFS =
event free survival; OS = overall survival.
Table 1: Demographic, clinical, histological, molecular and treatment characteristics of all patients (n = 400) and ana-
lysis of groups homogeneity (Pearson Chi
2-test) (Continued)
Yes 232 (93.2%) 141 (93.4%)
Internal mammary radiotherapy
No 16 (6.4%) 9 (6%) 0.517
Yes 233 (93.6%) 142 (94%)
Axillary radiotherapy
No 220 (88.4%) 120 (79.5%) 0.012
Yes 29 (11.6%) 31 (20.5%)
Abbreviations: BCT = breast conservative therapy; SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma;E R=
estrogen receptor; PR = progesterone receptor.
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Page 6 of 1183.2% in group A vs 79.2% in group B, a difference that
was not statistically significant (HR = 0.708; 95% CI,
0.455 to 1.128; log-rank P = .143) (Figure 2D).
Prognostic factors (table 2)
The proportional hazard model was used because of the
non homogeneity of patient characteristics between the
two groups A and B, to identify the positive treatment
effect of one group over the other, on LRFS (type 1),
EFS and OS.
-Analysis of prognostic factors using LRFS (type 1)
Univariate analysis showed that the factors influencing
LRFS were the tumor size (P = .016), with trend toward
significance for the ER status (P = 0.058) and CT proto-
col (anthracycline vs CMF) (P = .143). Multivariate ana-
lysis showed that the factors influencing LRFS were the
tumor size (P = .043), and trend toward significance
for CT protocol (HR = 0.347; 95% CI, 0.114 to 0.1.053;
P = .062), and ER status (P = .079).
-Analysis of prognostic factors using EFS Univariate ana-
lysis showed that the factors influencing EFS were the
lymph node involvement status (P = .004), tumor size
(P = .007), and trend toward significance for CT protocol
(anthracycline vs CMF) (P = .057). Multivariate analysis
showed that the factors influencing EFS were the lymph
node involvement status (P = .005), CT protocol (HR =
0.539; 95% CI, 0.344 to 0.846; P =0 . 0 1 2 ) ,a n dt u m o r
size (P = .047), trend toward significance for ER status
(P = .058) and number of cycles delivered concurrently
with RT (P = .051).
-Analysis of prognostic factors using OS Univariate
analysis showed that the factors influencing OS were
lymph node status (P = .002) and trend toward signifi-
cance for tumor size (P = .052). Multivariate analysis
showed that the factors influencing OS was the lymph
node status (P = .004) and CT protocol (HR = 0.63; 95%
CI, 0.401 to 0.991; P = .046).
Table 2 Factors influencing LRFS, EFS and OS (Cox proportional Hazard Model)
Analysis using locoregional recurrence free survival (type 1)
Factors Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Lymph node involvement: no vs yes 0.794 0.221 to 2.846 0.717 - - -
Tumour: pT1-2 vs pT3-4 0.273 0.095 to 0.787 0.016 0.326 0.11 to 0.963 0.043
SBR grade: 1-2 vs 3 0.692 0.232 to 2.066 0.509 - - -
ER status: positive vs negative 0.359 0.125 to 1.036 0.058 0.387 0.13 to 1.157 0.079
Age: ≥ 40 vs < 40 1.288 0.359 to 4.618 0.697 - - -
Regimen: anthracycline vs CMF 0.454 0.157 to 1.308 0.143 0.347 0.114 to 1.053 0.062
Number of cycles of CT delivered concurrently with RT: ≥ 2v s1 0.466 0.223 to 1.987 0.439 0.587 0.244 to 1.414 0.235
Analysis using event free survival
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Lymph node involvement: no vs yes 0.406 0.216 to 0.766 0.004 0.397 0.216 to 0.779 0.006
Tumour: pT1-2 vs pT3-4 0.552 0.356 to 0.855 0.007 0.624 0.392 to 0.993 0.047
SBR grade: 1-2 vs 3 0.801 0.508 to 1.265 0.341 0.971 0.598 to 1.576 0.906
ER status: positive vs negative 0.674 0.438 to 1.038 0.058 0.64 0.404 to 1.015 0.058
Age: ≥ 40 vs < 40 1.183 0.717 to 1.951 0.511 - - -
Regimen: anthracycline vs CMF 0.665 0.435 to 1.016 0.057 0.558 0.354 to 0.879 0.012
Number of cycles of CT delivered concurrently with RT: ≥ 2v s1 0.696 0.445 to 1.089 0.11 0.625 0.39 to 1.002 0.051
Analysis using overall survival
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Lymph node involvement: no vs yes 0.298 0.137 to 0.651 0.002 0.317 0.144 to 0.697 0.004
Tumour: pT1-2 vs pT3-4 0.619 0.381 to 1.005 0.052 0.719 0.429 to 1.208 0.213
SBR grade: 1-2 vs 3 0.694 0.427 to 1.130 0.142 0.781 0.466 to 1.309 0.347
ER status: positive vs negative 0.737 0.458 to 1.186 0.208 0.714 0.429 to 1.189 0.196
Age: ≥ 40 vs < 40 1.260 0.723 to 2.197 0.414 - - -
Regimen: anthracycline vs CMF 0.708 0.445 to 1.128 0.143 0.603 0.367 to 0.99 0.046
Number of cycles of CT delivered concurrently with RT: ≥ 2v s1 0.768 0.468 to 1.261 0.297 0.713 0.423 to 1.201 0.203
Abbreviations: HR = hazard ratio; CI = confidence interval; SBR = Scarf-Bloom-Richardson; ER = estrogen receptor; CT = chemotherapy; RT = radiotherapy
Ismaili et al. BMC Research Notes 2010, 3:247
http://www.biomedcentral.com/1756-0500/3/247
Page 7 of 113.2 Outcomes in patients who received more than 1 cycle
of CT concurrently with RT (n = 288)
The median follow-up period was 73 months, 72
months, and 74 months, for LRFS, EFS, and OS respec-
tively. Two patients developed loco-regional relapse
anthracycline subgroup (n = 162) vs 7 patients in CMF
subgroup (n = 126). The 5 years LRFS (type 1) rate was
equal to 98.7% in anthracycline subgroup vs 94.5% in
CMF subgroup (log-rank P=.038) (Figure 3A). The 5
years EFS rate was 84.2% in anthracycline subgroup vs
75.7% in CMF subgroup (log-rank P = .026) (Figure 3B).
The 5 years OS rate was 86.6% in anthracycline sub-
group vs 79.8% in CMF subgroup (log-rank P = .038)
(Figure 3C).
3.3 Outcomes in patients treated with BCT (n = 61)
The median follow-up period was 73 months, 73 months,
and 75 months, for LRFS, EFS, and OS respectively. The
5 years LRFS rate (type 1) was equal to 100% in
anthracycline subgroup vs 94.1% in CMF subgroup
(log-rank P=.049) (Figure 3D). The 5 years EFS rate
was 94.2% in anthracycline subgroup vs 84% in CMF
subgroup (log-rank P = .04) (Figure 3E). The 5 years
OS rate was 94.2% in anthracycline subgroup vs 84%
in CMF subgroup (log-rank P = .259) (Figure 3F).
Discussion
T h em a i na d v a n t a g e so fC C R Ta r e :1 .d e l i v e r i n gb o t h
treatments of CT and RT at same time; 2. biological
synergy effect that can increase the efficacy of the treat-
ment [34]. A CT based on liposomal doxorubicin, pacli-
taxel and vinorelbine, with concomitant RT in non
operable and recurrent disease, was found to be of
good efficacy and tolerability [34,35]. Reirradiation with
concomitant CT was shown to have positive effect
[34,36]. In adjuvant setting, CCRT has successfully been
achieved by the concurrent use of CMF or taxanes with
WBI [20-23].
Few prospective studies investigated CCRT using
anthracycline regimen. The authors showed high rate of
high grade skin toxicity, and more cardiac dysfunction,
and concluded that this protocol cannot be used in
practice [25-27]. However, in a recent phase I trial, the
authors showed that PBI with concurrent dose dense
doxorubicin and cyclophosphamide induced an accepta-
ble hematologic and nonhematologic toxicity profile
with likelihood of RD ≥ grade 2 is ≤ 11% [29]. These
results were in favor of the use of CCRT based on
anthracycline regimen and this is why we suggest the
evaluation of concurrent versus sequential therapy in
Figure 3 Panels A, B, and C: Anthracycline (n = 162) compared to CMF (n = 126) in the subgroup of patients treated with ≥ 2 cycles
of concurrent CT with RT: Kaplan-Meier estimates of LRFS (Panel A), EFS (Panel B), and OS (Panel C); Panels D, E, and F: Anthracycline
(n = 40) compared to CMF (n = 21) in the subgroup of patients treated with BCT (n = 61): Kaplan-Meier estimates of LRFS (Panel D),
EFS (Panel E), and OS (Panel F). LRFS = locoregional recurrence free survival; EFS = event free survival; OS = overall survival.
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ern radiation techniques. In our previous investigation
we evaluated two concurrent protocols administered
either with anthracycline regimen or with CMF in adju-
vant setting and confirmed the beneficial effect of
anthracycline based protocol in locoregional control
with acceptable toxicity profile over the CMF [28].
After 74.5 months median follow-up, we found no sta-
tistical difference in the OS between the two therapeutic
groups A and B, which can be explained by the fact that
group A was characterized by poorer prognosis (more
lymph node involvement). However, we showed a trend
toward significance for EFS in favor of anthracycline
(log-rank P = .057). In addition, when only the isolated
locoregional events were considered, the LRFS at 5
years was significantly higher in group A than group B
(98.7% vs 95.3%; log-rank P = .034). To confirm the
beneficial effect of anthracycline we conducted subgroup
analyses. The first subgroup concerned patients treated
with ≥ 2 cycles of concurrent CT (n = 288 from A and
B) and we showed that LRFS, EFS and OS were statisti-
cally higher in the anthracycline based treatment than in
CMF. The second sub group concerned patients treated
with BCT (n = 61 from A and B) and we showed that
LRFS and EFS were statistically higher in anthracycline
than in CMF. In addition, using the multivariate Cox
proportional hazard regression models analysis, we con-
firmed that the anthracycline regimen favorably influ-
enced the LRFS (type 1) (P = .062), the EFS (P = .007),
and OS (P = .046) (table 2).
However, in adjuvant setting, it has been demon-
strated that anthracycline and taxanes containing regi-
mens decreased relapse and improved survival.
Consequently, our results may be explained by the
effect of anthracycline regimen and not by the use of
CCRT [24,37].
Three recent randomized phase III trials were con-
ducted to compare the sequential protocol to the conco-
mitant protocol. In the first trial, 716 patients were treated
by BCT and randomized into 2 groups (ARCOSEIN
study) [38]. In the first group, the patients were treated by
the FNC protocol (5-fluoro-uracil 500 mg/m2, mitoxan-
trone 12 mg/m
2 and cyclophosphamide 500 mg/m
2) with
concomitant RT. In the second group, the patients were
treated by the FNC protocol followed by RT. Arcangely
et al. [39], randomly assigned 206 patients (after quadran-
tectomy and axillary dissection) to concurrent or sequen-
tial treatments using CMF based CT. In the third trial,
Rouessé et al. [40], randomly assigned 638 patients with
prior breast surgery and positive axillary dissection (from
which 416 were BCT) to receive CCRT (FNC protocol)
or CT (fluorouracil, epirubicin, and cyclophosphamide
protocol) followed by RT. No differences in 5-years LRFS,
disease-free survival and OS were observed between the
2 treatment groups in the 3 trials. Nevertheless, in the
ARCOSEIN study the authors identified a significant
decrease in the risk of locoregional recurrence with CCRT
for node-positive patients. Rouessé et al. [40], showed that
concurrent treatment has a significantly better locoregio-
nal control in node-positive breast cancer after BCT.
In our study we found significantly higher locoregional
control of the disease and a trend for a higher rate of
5 years EFS in anthracycline group vs CMF group. And
we found a superior effect of concurrent use of anthra-
cycline over CMF in terms of LRFS and EFS in the sub-
group of patients treated with BCT. In addition, in the
subgroup of patient treated with ≥ 2 cycles of concur-
rent CT, we confirmed the significant beneficial effect of
the anthracycline in terms of LRFS, EFS and OS.
The main limitation of the 3 European trials was the
use of CMF protocol and FNC protocol which have a
safer toxicity profile when radiation treatment was used
without the use of anthracycline and taxane regimens.
CMF and FNC are older CT regimen used in the past;
however more recently anthracyclines and taxanes con-
taining regimens have become standard, and are demon-
strated to have improved survival and local recurrence
outcomes.
In ARCOSEIN study, moderate acute locoregional
toxicities were found in the concomitant arm. Rouessé
et al. [40] presented more frequent grade 2 skin toxici-
ties in the concomitant arm, and more subclinical LVFE
events at 1 year. In our study we showed more haema-
tologic toxicity when the treatment was based on
anthracycline with significantly more grade 3-4 neutro-
penia. Grade 2-3 anemia and grade ≥ 2 thrombopenia
were more frequent in anthracycline group but the dif-
ferences were not significant.
In our study, we found more respiratory symptoms
and high grade (≥ grade 2) RD toxicity (4.8% vs 1.3%) in
anthracycline group versus CMF group. We note how-
ever that dermatitis toxicity was not routinely evaluated
like other adverse events as we would expect much
higher dermatitis rates with concurrent taxane/radiation.
Our retrospective study showed different limitations,
because it implicated potential bias in the choice of
treatment. In addition to the lack of cardiac toxicity eva-
luation which constituted the major limitation (only 2%
[n = 9] had assessment of cardiac function via LVEF
measurement). However, 50% of the cases were left-
sided breast cancers and would probability induce a
high risk of cardiac toxicity.
Conclusion
From the present 5 years nonrandomized investigation
we concluded that the treatment based on anthracycline
and concurrent RT reduced breast cancer relapse
rate including locoregional relapses and significantly
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Page 9 of 11improved LRFS, EFS and OS in the patients receiving
more than 1 cycle of concurrent CT. In multivariate
analysis we confirmed that the anthracycline regimens
had a positive effect on LRFS, EFS and OS. There were
more hematologic and non hematologic toxicities in the
anthracycline group. Anthracyclines and WBI cannot be
administered concurrently before further investigations
to determine efficacy and safety of anthracycline based
treatment.
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